MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder

Akaishi, 2016, MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study, J. Neurol. Neurosurg. Psychiatry, 87, 446, 10.1136/jnnp-2014-310206 Baumann, 2015, Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein, J. Neurol. Neurosurg. Psychiatry, 86, 265, 10.1136/jnnp-2014-308346 Berger, 2003, Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event, N. Engl. J. Med., 349, 139, 10.1056/NEJMoa022328 Brilot, 2009, Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease, Ann. Neurol., 66, 833, 10.1002/ana.21916 Brunner, 1989, Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats, J. Neurochem., 52, 296, 10.1111/j.1471-4159.1989.tb10930.x Chalmoukou, 2015, Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis, Neurol. Neuroimmunol. Neuroinflamm., 2, e131, 10.1212/NXI.0000000000000131 Chen, 2017, Muscle damage in patients with neuromyelitis optica spectrum disorder, Neurol. Neuroimmunol. Neuroinflamm., 4, e400, 10.1212/NXI.0000000000000400 Dale, 2014, Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton, Neurol. Neuroimmunol. Neuroinflamm., 1, e12, 10.1212/NXI.0000000000000012 Di Pauli, 2015, Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology, Neurol. Neuroimmunol. Neuroinflamm., 2, e175, 10.1212/NXI.0000000000000175 Hacohen, 2018, Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease, JAMA Neurol., 75, 478, 10.1001/jamaneurol.2017.4601 Huppke, 2013, Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients, Multiple Scler., 19, 941, 10.1177/1352458512466317 Hamid, 2017, What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients, J. Neurol., 264, 2088, 10.1007/s00415-017-8596-7 Hamid, 2018, Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs. aquaporin 4 IgG disease, JAMA Neurol., 75, 65, 10.1001/jamaneurol.2017.3196 Havla, 2017, Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration, J. Neurol., 264, 139, 10.1007/s00415-016-8333-7 Huppke, 2013, Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients, Multiple Scler., 19, 941, 10.1177/1352458512466317 Hyun, 2017, Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases, J. Neurol. Neurosurg. Psychiatry, 88, 811, 10.1136/jnnp-2017-315998 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome, J. Neuroinflamm., 13, 281, 10.1186/s12974-016-0719-z Jarius, 2016, Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case, Multiple Scler., 22, 1541, 10.1177/1352458515622986 Jarius, 2008, Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica, Nat. Clin. Pract. Neurol., 4, 202, 10.1038/ncpneuro0764 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J. Neuroinflamm., 13, 280, 10.1186/s12974-016-0718-0 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, J. Neuroinflamm., 13, 279, 10.1186/s12974-016-0717-1 Jarius, 2012, Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients, J. Neuroinflamm., 9, 14, 10.1186/1742-2094-9-14 Jarius, 2018, MOG encephalomyelitis: international recommendations on diagnosis and antibody testing, J. Neuroinflamm., 15, 134, 10.1186/s12974-018-1144-2 Johns, 1999, The structure and function of myelin oligodendrocyte glycoprotein, J. Neurochem., 72, 1, 10.1046/j.1471-4159.1999.0720001.x Jurynczyk, 2017, Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis, Brain, 140, 617, 10.1093/brain/aww350 Jurynczyk, 2017, Clinical presentation and prognosis in MOG-antibody disease: a UK study, Brain, 140, 3128, 10.1093/brain/awx276 Jurynczyk, 2017, Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease, J. Neurol. Neurosurg. Psychiatry, 88, 132, 10.1136/jnnp-2016-314005 Kaneko, 2016, Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies, J. Neurol. Neurosurg. Psychiatry, 87, 1257, 10.1136/jnnp-2015-312676 Kim, 2015, MRI characteristics of neuromyelitis optica spectrum disorder: an international update, Neurology, 84, 1165, 10.1212/WNL.0000000000001367 Kim, 2011, Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years, Arch. Neurol., 68, 1412, 10.1001/archneurol.2011.154 Kim, 2015, Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS, Neurol. Neuroimmunol. Neuroinflamm., 2, e163, 10.1212/NXI.0000000000000163 Kitley, 2013, Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies, JAMA Neurol., 70, 1375, 10.1001/jamaneurol.2013.3890 Kitley, 2014, Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study, JAMA Neurol., 71, 276, 10.1001/jamaneurol.2013.5857 Kiyat-Atamer, 2013, Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients, Eur. J. Neurol., 20, 781, 10.1111/ene.12058 Kremer, 2014, Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients, Multiple Scler., 20, 843, 10.1177/1352458513507822 Kuhle, 2007, Lack of association between antimyelin antibodies and progression to multiple sclerosis, N. Engl. J. Med., 356, 371, 10.1056/NEJMoa063602 Lampasona, 2004, Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects, Neurology, 62, 2092, 10.1212/01.WNL.0000127615.15768.AE Lim, 2005, Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis, Multiple Scler., 11, 492, 10.1191/1352458505ms1187sr Mader, 2011, Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, J. Neuroinflamm., 8, 184, 10.1186/1742-2094-8-184 Malik, 2014, Transient hyperckemia in the setting of neuromyelitis optica (NMO), Muscle Nerve, 50, 859, 10.1002/mus.24298 Mariotto, 2017, Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study, J. Neurol., 264, 2420, 10.1007/s00415-017-8635-4 Matiello, 2008, NMO-IgG predicts the outcome of recurrent optic neuritis, Neurology, 70, 2197, 10.1212/01.wnl.0000303817.82134.da Mealy, 2017, Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders, Multiple Scler. Misu, 2013, Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica, Acta Neuropathol., 125, 815, 10.1007/s00401-013-1116-7 Montcuquet, 2017, Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders, Multiple Scler., 23, 1377, 10.1177/1352458516678474 Moura, 2015, Anti-MOG (myelin oligodendrocyte glycoprotein)-positive severe optic neuritis with optic disc ischaemia and macular star, Neuroophthalmology, 39, 285, 10.3109/01658107.2015.1084332 O'Connor, 2007, Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein, Nat. Med., 13, 211, 10.1038/nm1488 Ogawa, 2017, MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy, Neurol. Neuroimmunol. Neuroinflamm., 4, e322, 10.1212/NXI.0000000000000322 Oh, 2012, Neuromyelitis optica: an antibody-mediated disorder of the central nervous system, Neurol. Res. Int., 2012, 10.1155/2012/460825 Pache, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients, J. Neuroinflamm., 13, 282, 10.1186/s12974-016-0720-6 Pandit, 2018, Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis, Neurol. Neuroimmunol. Neuroinflamm., 5, e412, 10.1212/NXI.0000000000000412 Pearce, 2005, Neuromyelitis optica, Spinal Cord, 43, 631, 10.1038/sj.sc.3101758 Pekcevik, 2016, Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging, Multiple Scler., 22, 302, 10.1177/1352458515591069 Peschl, 2017, Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases, Front. Immunol., 8, 529, 10.3389/fimmu.2017.00529 Pham-Dinh, 1993, Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex, Proc. Natl. Acad. Sci. USA, 90, 7990, 10.1073/pnas.90.17.7990 Popescu, 2016, Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis, Handb Clin Neurol, 133, 95, 10.1016/B978-0-444-63432-0.00006-2 Probstel, 2011, Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis, Neurology, 77, 580, 10.1212/WNL.0b013e318228c0b1 Ramanathan, 2018, Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J. Neurol. Neurosurg. Psychiatry, 89, 127, 10.1136/jnnp-2017-316880 Ramanathan, 2016, Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis, Multiple Scler., 22, 470, 10.1177/1352458515593406 Ramanathan, 2014, Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Neurol. Neuroimmunol. Neuroinflamm., 1, e40, 10.1212/NXI.0000000000000040 Reindl, 1999, Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study, Brain, 122, 2047, 10.1093/brain/122.11.2047 Rostasy, 2012, Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis, Arch. Neurol., 69, 752, 10.1001/archneurol.2011.2956 Saini, 2010, Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity, J. Neuroimmunol., 221, 68, 10.1016/j.jneuroim.2010.02.007 Sato, 2014, Seronegative neuromyelitis optica spectrum–the challenges on disease definition and pathogenesis, Arq. Neuropsiquiatr., 72, 445, 10.1590/0004-282X20140032 Sato, 2014, Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, 82, 474, 10.1212/WNL.0000000000000101 Sepulveda, 2016, Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus, Neurol. Neuroimmunol. Neuroinflamm., 3, e225, 10.1212/NXI.0000000000000225 Spadaro, 2016, Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis, Neurol. Neuroimmunol. Neuroinflamm., 3, e257, 10.1212/NXI.0000000000000257 Spadaro, 2015, Histopathology and clinical course of MOG-antibody-associated encephalomyelitis, Ann. Clin. Trans. Neurol., 2, 295, 10.1002/acn3.164 Stefferl, 2000, The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis, J. Neural Transm. Suppl., 123 Stiebel-Kalish, 2017, Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study, PLoS One, 12, 10.1371/journal.pone.0170847 Wang, 2016, Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD, Neurology, 87, 229, 10.1212/WNL.0000000000002844 Waters, 2015, MOG cell-based assay detects non-MS patients with inflammatory neurologic disease, Neurol. Neuroimmunol. Neuroinflamm., 2, e89, 10.1212/NXI.0000000000000089 Waters, 2012, Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays, Neurology, 78, 665, 10.1212/WNL.0b013e318248dec1 Weinshenker, 2006, Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis, Ann. Neurol., 59, 566, 10.1002/ana.20770 Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729 Zamvil, 2015, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder, Neurol. Neuroimmunol. Neuroinflamm., 2, e62, 10.1212/NXI.0000000000000062 Zekeridou, 2015, Aquaporin-4 autoimmunity, Neurol. Neuroimmunol. Neuroinflamm., 2, e110, 10.1212/NXI.0000000000000110